Piramal Pharma Gains 3.25%: Technical and Valuation Shifts Mark the Week

6 April 2026: Week Opens Steady Amid Market Stability

The stock commenced the week at ₹141.50, maintaining a stable position relative to the previous close. Trading volume was moderate at 96,495 shares, while the Sensex closed at 33,229.93, setting a baseline for the week’s subsequent movements. No significant news impacted the stock on this day, and the price action reflected a cautious market environment.

7 April 2026: Slight Dip Despite Sensex Gains

Piramal Pharma’s share price edged down marginally by 0.32% to ₹141.05, on reduced volume of 48,782 shares. This decline contrasted with the Sensex’s 0.50% gain to 33,395.05, indicating relative underperformance. The subdued price movement suggested investor hesitation ahead of anticipated valuation updates and technical reviews.

8 April 2026: Valuation Shifts to Attractive Amid Challenging Market Returns

The stock rebounded strongly, gaining 2.02% to close at ₹143.90 on heavy volume of 172,933 shares. This rise coincided with a key valuation reassessment that upgraded Piramal Pharma’s rating from fair to attractive. Despite a negative price-to-earnings ratio of -130.89 reflecting ongoing losses, the stock’s price adjustment relative to earnings expectations improved its valuation appeal compared to sector peers.

Enterprise value to EBITDA stood at 22.36, lower than competitors such as Wockhardt and AstraZeneca, while the price-to-book value ratio of 2.32 remained modest. However, profitability metrics remained weak, with a return on capital employed of 2.66% and a negative return on equity of -0.55%. These factors underscored the valuation’s attractiveness as a function of depressed earnings rather than operational strength.

9 April 2026: Technical Momentum Shift and Mojo Score Upgrade

The stock closed slightly lower at ₹142.90, down 0.69%, on volume of 148,348 shares, while the Sensex declined 0.49% to 34,521.99. Despite the dip, this day marked a significant technical and rating development. MarketsMOJO upgraded Piramal Pharma’s Mojo Score from 28.0 (Strong Sell) to 34.0 (Sell), reflecting improved technical indicators and valuation metrics.

Technical analysis revealed a shift from strongly bearish to mildly bearish momentum. The weekly MACD remained bearish but softened, and the monthly MACD moved to mildly bearish. Bollinger Bands indicated mild bearishness, while the Relative Strength Index showed neutral momentum. Dow Theory on the weekly chart turned mildly bullish, supported by a mildly bullish on-balance volume, suggesting cautious accumulation.

Valuation metrics also improved, with the price-to-earnings ratio at -134.14 and enterprise value to EBITDA at 22.82, both more attractive relative to expensive peers like Ajanta Pharma and J B Chemicals. However, financial challenges persisted, including a loss of ₹95.99 crores before tax in Q3 FY25-26 and a high debt-to-EBITDA ratio of 4.17 times, signalling elevated leverage risks.

10 April 2026: Week Closes on a Positive Note

Piramal Pharma ended the week on a strong footing, gaining 2.24% to ₹146.10 on volume of 96,354 shares. The Sensex also advanced 1.40% to 35,004.96, but the stock’s weekly gain of 3.25% still lagged the benchmark’s 5.34% rise. The closing price marked the week’s high, reflecting renewed investor interest amid the technical and valuation upgrades.

Despite this positive close, the stock remains well below its 52-week high of ₹241.00, highlighting the ongoing challenges in regaining prior valuation levels. The company’s small-cap status and weak profitability metrics continue to temper enthusiasm, even as technical signals suggest a potential stabilisation phase.

Daily Price Performance vs Sensex

Key Takeaways

Valuation Improvement: The shift from fair to attractive valuation grades, despite negative earnings, highlights a market adjustment that positions Piramal Pharma as relatively undervalued compared to expensive sector peers. This is primarily driven by a depressed share price rather than operational turnaround.

Technical Momentum Shift: The upgrade in technical indicators and Mojo Score from Strong Sell to Sell reflects a cautious improvement in market sentiment. Mildly bullish signals from Dow Theory and on-balance volume suggest early signs of accumulation, though bearish moving averages and MACD indicate ongoing short-term challenges.

Financial and Profitability Challenges: Persistent losses, negative return on equity, and high leverage remain significant headwinds. The company’s Q3 FY25-26 results showed steep declines in profit before tax and net profit, underscoring the need for operational recovery to sustain any positive momentum.

Market Performance Context: While the stock gained 3.25% over the week, it underperformed the Sensex’s 5.34% rise. Longer-term returns remain strong, with a three-year gain exceeding 110%, but recent underperformance and volatility highlight ongoing risks.

Conclusion

Piramal Pharma Ltd’s week was characterised by a nuanced blend of cautious optimism and persistent challenges. The valuation upgrade to attractive and the technical momentum shift to mildly bearish with a Mojo Score upgrade to Sell signal a potential stabilisation phase after a prolonged downtrend. However, weak profitability, high leverage, and underperformance relative to the broader market temper enthusiasm.

Investors should note that while the stock shows signs of bottoming out, the fundamental financial pressures remain significant. The company’s small-cap status adds volatility risk, and the absence of strong earnings recovery suggests that any upward momentum may be fragile. Close monitoring of operational improvements and market sentiment will be essential to assess the sustainability of this tentative rebound.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →